Does urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli show same antibiotic resistance when it recurs?

被引:10
|
作者
Ahn, Sun Tae [1 ]
Kim, Sang Woo [1 ]
Kim, Jong Wook [1 ]
Park, Hong Seok [1 ]
Moon, Du Geon [1 ]
Oh, Mi Mi [1 ]
机构
[1] Korea Univ, Dept Urol, Guro Hosp, 148 Gurodong Ro, Seoul 152703, South Korea
关键词
Urinary tract infection; Extended-spectrum beta-lactamase; Escherichia coli; Longitudinal study; ACUTE UNCOMPLICATED CYSTITIS; ANTIMICROBIAL SUSCEPTIBILITY; RISK-FACTORS; ENTEROBACTERIACEAE; GUIDELINES; MANAGEMENT; EMERGENCE; STRAINS; WOMEN;
D O I
10.1016/j.jiac.2019.02.006
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
This study was performed to evaluate what percentage of urinary tract infections (UTIs) caused by extended spectrum beta-lactamase (ESBL)-producing strains recurs with ESBL-producing strains during follow up and to assess the risk factors for recurrence with ESBL-producing Escherichia coli strains on subsequent first recurrence episode. We enrolled female patients with UTIs caused by ESBL-producing E. coli between May 2012 and December 2015, who were longitudinally followed up for at least 24 months. Among the 206 patients with ESBL positive UTI, 180 completed the study. 60 (60/180, 33.3%) of patient with first episode of UTI caused by ESBL-producing E. coli experienced recurrent UTIs during follow up. Of 60 patients, 43 (43/60, 71.7%) recurred with ESBL-producing E. coli on the first UTI recurrence episode. On multivariate analysis, the time to recurrence and history of cephalosporin usage in the last 6 months were identified as risk factors for recurrence with ESBL-producing E. coli per se (odds ratio [OR] = 0.9, 95% confidence interval [CI] 0.8-1.0, p = 0.030 and OR = 27.0, 95% CI 2.4-299.8, p = 0.007, respectively). These findings show that high proportion of patient with UTI caused by ESBL-producing E. coli recurs with ESBL-producing E. coli on subsequent recurrence episode. While result of antibiotic susceptibility cannot be identified on the visit day empirical treatment should be referred to the antecedent antibiotic resistance profile in patients whose previous UTIs were due to ESBL-producing strains. (c) 2019 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:498 / 502
页数:5
相关论文
共 50 条
  • [31] Extended-spectrum β-lactamase-producing Escherichia coli strains in the feces of carriers contribute substantially to urinary tract infections in these patients
    Niki, M.
    Hirai, I.
    Yoshinaga, A.
    Ulzii-Orshikh, L.
    Nakata, A.
    Yamamoto, A.
    Yamamoto, M.
    Yamamoto, Y.
    INFECTION, 2011, 39 (05) : 467 - 471
  • [32] Prevalence and antibiotic resistance pattern of extended spectrum beta lactamase producing Escherichia coli isolated from urinary tract infection
    Rajabnia, Mohsen
    Forghani, Mohammad Saad
    Hasani, Sabah
    Bahadoram, Mohammad
    Mohammadi, Mahsa
    Barahman, Maedeh
    JOURNAL OF RENAL INJURY PREVENTION, 2019, 8 (02): : 78 - 81
  • [33] Retrospective evaluation of appropriate dosing of cefmetazole for invasive urinary tract infection due to extended-spectrum β-lactamase-producing Escherichia coli
    Hamada, Yukihiro
    Matsumura, Yasufumi
    Nagashima, Maki
    Akazawa, Tsubasa
    Doi, Yohei
    Hayakawa, Kayoko
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2021, 27 (11) : 1602 - 1606
  • [34] Effectiveness of cefmetazole versus meropenem for invasive urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli
    Hayakawa, Kayoko
    Matsumura, Yasufumi
    Uemura, Kohei
    Tsuzuki, Shinya
    Sakurai, Aki
    Tanizaki, Ryutaro
    Shinohara, Koh
    Hashimoto, Takehiro
    Hase, Ryota
    Matono, Takashi
    Kato, Hideaki
    Mawatari, Momoko
    Hara, Hiroshi
    Hamada, Yukihiro
    Saito, Sho
    Ohmagari, Norio
    Doi, Yohei
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2023, 67 (10)
  • [35] Factors Associated with Acute Community-Acquired Pyelonephritis Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli
    Romero Nieto, Monica
    Maestre Verdu, Sara
    Gil, Vicente
    Perez Barba, Carlos
    Quesada Rico, Jose Antonio
    Pascual Perez, Reyes
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (21)
  • [36] Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli in patients with cancer
    Ha, Young Eun
    Kang, Cheol-In
    Cha, Min Kyeong
    Park, So Yeon
    Wi, Yu Mi
    Chung, Doo Ryeon
    Peck, Kyong Ran
    Lee, Nam Yong
    Song, Jae-Hoon
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2013, 42 (05) : 403 - 409
  • [37] Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae
    Seung Beom Han
    Sung Chul Lee
    Soo Young Lee
    Dae Chul Jeong
    Jin Han Kang
    BMC Infectious Diseases, 15
  • [38] Extended-spectrum β-lactamase-producing Escherichia coli bacteremia: Comparison of pediatric and adult populations
    Tsai, Wan-Lin
    Hung, Chih-Hsin
    Chen, Hui-An
    Wang, Jiun-Ling
    Huang, I-Fei
    Chiou, Yee-Hsuan
    Chen, Yao-Shen
    Lee, Susan Shin-Jung
    Hung, Wan-Yu
    Cheng, Ming-Fang
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2018, 51 (06) : 723 - 731
  • [39] A clinical prediction tool for extended-spectrum β-lactamase-producing Enterobacteriaceae urinary tract infection
    Liu, Hui
    Qiu, Suishan
    Chen, Minghao
    Lyu, Jun
    Yu, Guangchao
    Xue, Lianfang
    BMC INFECTIOUS DISEASES, 2022, 22 (01)
  • [40] Non-carbapenem therapy of urinary tract infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae
    de La Blanchardiere, A.
    Dargere, S.
    Guerin, F.
    Daurel, C.
    Saint-Lorant, G.
    Verdon, R.
    Cattoir, V.
    MEDECINE ET MALADIES INFECTIEUSES, 2015, 45 (05): : 169 - 172